Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943618 · ClinicalTrials.gov registry record · Phase 3
Combining Varenicline and Bupropion for Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
- 1
- Study location
NCT00943618: Completed Phase 3 study of Smoking Cessation, sponsored by M.D. Anderson Cancer Center.
NCT00943618 is a Phase 3 study of Smoking Cessation that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 641 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00943618, a Phase 3 study of Smoking Cessation, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is learn if the combination of Chantix (varenicline) and Zyban (bupropion) is more effective at helping people to quit smoking than varenicline when given alone. Researchers also want to learn if this drug combination can reduce cravings and other negative symptoms of nicotine withdrawal better than varenicline does alone. The safety of this drug combination will also be tested.
Primary Outcome
Prolonged Abstinence is defined as no smoking from the quit date to 12 Months post quit date.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Varenicline
- DRUG Bupropion
- BEHAVIORAL Counseling/Phone Calls
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2010-05-17 |
| Est. Completion | 2021-09-09 |
| Phase | Phase 3 |
What the finished NCT00943618 record still lists
NCT00943618 is an interventional study that assigns participants to a tested intervention. The registered 641 participants enrollment target is mid-sized for trials with a published cap, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00943618 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00943618 about?
NCT00943618 is a clinical study titled "Combining Varenicline and Bupropion for Smoking Cessation". The goal of this clinical research study is learn if the combination of Chantix (varenicline) and Zyban (bupropion) is more effective at helping people to quit smoking than varenicline when given alone. Researchers also want to learn if this drug combination can reduce cravings and other negative sy...
What is the current status of trial NCT00943618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2010-05-17. Estimated completion is 2021-09-09.
What conditions does trial NCT00943618 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00943618?
The interventions under investigation include: Placebo (OTHER), Varenicline (DRUG), Bupropion (DRUG), Counseling/Phone Calls (BEHAVIORAL).
Who is sponsoring clinical trial NCT00943618?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00943618 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00943618's enrollment target sits among peer trials
641 42nd of 188 higher than 147 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06319820 · 641 participants · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT06625060 · 641 participants · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI